OCGN

Ocugen Inc

Add to Watchlist

Advanced Chart

0.989

-0.009(-0.901%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.010

Open

0.980

VWAP

0.98

Vol

454.72K

Mkt Cap

291.84M

Low

0.960

Amount

445.62K

EV/EBITDA(TTM)

Total Shares

257.35M

292.85M

EV/OCF(TTM)

P/S(TTM)

60.55

Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

333.33K

-77.49%

-0.060

+20%

325.00K

-57.46%

-0.060

+20%

300.00K

-73.59%

-0.060

+20%

Estimates Revision

The market is revising Upward the revenue expectations for Ocugen, Inc. (OCGN) for FY2025, with the revenue forecasts being adjusted by 68.77% over the past three months. During the same period, the stock price has changed by 41.34%.

Revenue Estimates for FY2025

Revise Upward

+68.77%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-10.26%

In Past 3 Month

Stock Price

Go Up

+41.34%

In Past 3 Month

4 Analyst Rating

405.36% Upside

Wall Street analysts forecast OCGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OCGN is 5.00 USD with a low forecast of 1.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

405.36% Upside

Current: 0.989

Low

1.00

Averages

5.00

High

8.00

405.36% Upside

Current: 0.989

Low

1.00

Averages

5.00

High

8.00

H.C. Wainwright

Buy

downgrade

$8 -> $7

2025-05-12

Reason

H.C. Wainwright

Price Target

$8 -> $7

2025-05-12

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Ocugen to $7 from $8 and keeps a Buy rating on the shares following the Q1 report. The firm says the company is targeting OCU400 approval in 2026.

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

2025-03-06

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

2025-03-06

Reiterates

Strong Buy

Reason

Chardan Capital

Daniil Gataulin

Strong Buy

Maintains

$6 → $7

2025-03-06

Reason

Chardan Capital

Daniil Gataulin

Price Target

$6 → $7

2025-03-06

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Maintains

$7 → $8

2025-02-13

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$7 → $8

2025-02-13

Maintains

Strong Buy

Reason

Latest data shows the largest indicative borrow rate increases among liquid option names include: Azul (AZUL) 70.69% +1.20, Soho House + Co Inc (SHCO) 1.61% +0.98, X4 Pharmaceuticals (XFOR) 2.32% +0.68, Autobot Holdings (ARBE) 8.92% +0.42, Gorilla Technology Group Inc (GRRR) 35.63% +0.29, Ocugen (OCGN) 2.92% +0.28, Plug Power (PLUG) 8.36% +0.22, Equinor (EQNR) 4.81% +0.21, Hecla Mining (HL) 0.58% +0.20, and SolarEdge (SEDG) 0.83% +0.19.

Chardan Capital

Daniil Gataulin

Strong Buy

Maintains

2025-02-13

Reason

Chardan Capital

Daniil Gataulin

Price Target

2025-02-13

Maintains

Strong Buy

Reason

Chardan Capital

Daniil Gataulin

Strong Buy

Maintains

2025-01-23

Reason

Chardan Capital

Daniil Gataulin

Price Target

2025-01-23

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Ocugen Inc (OCGN.O) is -4.16, compared to its 5-year average forward P/E of -27.06. For a more detailed relative valuation and DCF analysis to assess Ocugen Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-27.06

Current PE

-4.16

Overvalued PE

73.45

Undervalued PE

-127.57

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

139.30

Current PS

215.20

Overvalued PS

373.52

Undervalued PS

-94.93